{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:04:07Z","timestamp":1763017447846},"reference-count":24,"publisher":"Cambridge University Press (CUP)","issue":"6","license":[{"start":{"date-parts":[[2014,9,23]],"date-time":"2014-09-23T00:00:00Z","timestamp":1411430400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["journals.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Cardiol Young"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Introduction:<\/jats:italic> Subclinical hypothyroidism or mild thyroid failure is a common problem in patients without known thyroid disease. <jats:italic>Methods:<\/jats:italic> Demographic and analytical data were collected in 309, of which 181 were male and 128 were female, congenital heart disease (CHD) patients. CHD patients with thyroid-stimulating hormone above 5.5 mIU\/L were also followed up from an analytical point of view to determine changes in serum glucose, cholesterol, N-terminal pro b-type natriuretic peptide, and C-reactive protein concentrations. <jats:italic>Results:<\/jats:italic> Of the CHD patients, 35 (11.3%) showed thyroid-stimulating hormone concentration above 5.5 mIU\/L. Of them, 27 were followed up during 2.4\u00b11.2 years \u2013 10 were under thyroid hormone replacement treatment, and 17 were not. Of the 27 patients (25.9%), 7 with subclinical hypothyroidism had positive anti-thyroid peroxidase, and 3 of them (42.8%) with <jats:bold>positive<\/jats:bold> anti-thyroid peroxidase had Down syndrome. Down syndrome and hypoxaemic CHD patients showed higher thyroid-stimulating hormone concentrations than the rest of the congenital patients (p&lt;0.001). No significant differences were observed in serum thyroxine, creatinine, uric acid, lipids, C-reactive protein, or N-terminal pro b-type natriuretic peptide concentrations before and after the follow-up in those CHD patients with thyroid-stimulating hormone above 5.5 mIU\/L whether or not they received levothyroxine therapy. <jats:italic>Conclusions:<\/jats:italic> CHD patients with subclinical hypothyroidism showed no significant changes in serum thyroxine, cholesterol, C-reactive protein, or N-terminal pro b-type natriuretic peptide concentrations whether or not they were treated with thyroid hormone replacement therapy.<\/jats:p>","DOI":"10.1017\/s1047951114001711","type":"journal-article","created":{"date-parts":[[2014,9,23]],"date-time":"2014-09-23T13:52:40Z","timestamp":1411480360000},"page":"1111-1118","update-policy":"http:\/\/dx.doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":3,"title":["Follow-up of congenital heart disease patients with subclinical hypothyroidism"],"prefix":"10.1017","volume":"25","author":[{"given":"Efr\u00e9n","family":"Mart\u00ednez-Quintana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fayna","family":"Rodr\u00edguez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2014,9,23]]},"reference":[{"key":"S1047951114001711_ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-012-0571-6"},{"key":"S1047951114001711_ref9","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12011"},{"key":"S1047951114001711_ref22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2532"},{"key":"S1047951114001711_ref20","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.10.7973"},{"key":"S1047951114001711_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9629(15)40640-8"},{"key":"S1047951114001711_ref13","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.52.89"},{"key":"S1047951114001711_ref19","first-page":"2993","article-title":"Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature","volume":"85","author":"Danese","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"S1047951114001711_ref5","doi-asserted-by":"publisher","DOI":"10.1067\/mje.2002.120202"},{"key":"S1047951114001711_ref3","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.2.8182"},{"key":"S1047951114001711_ref6","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-1021"},{"key":"S1047951114001711_ref8","doi-asserted-by":"publisher","DOI":"10.4103\/2045-8932.97592"},{"key":"S1047951114001711_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(05)70281-4"},{"key":"S1047951114001711_ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1995.tb01894.x"},{"key":"S1047951114001711_ref24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1039"},{"key":"S1047951114001711_ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2005.02388.x"},{"key":"S1047951114001711_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(80)80019-9"},{"key":"S1047951114001711_ref17","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1C376"},{"key":"S1047951114001711_ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.2.228"},{"key":"S1047951114001711_ref2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.14.1533"},{"key":"S1047951114001711_ref23","doi-asserted-by":"publisher","DOI":"10.5455\/medarh.2012.66.364-368"},{"key":"S1047951114001711_ref11","first-page":"240","article-title":"The effects of amiodarone on the thyroid","volume":"22","author":"Martino","year":"2001","journal-title":"Endoc Rev"},{"key":"S1047951114001711_ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.1993.tb11660.x"},{"key":"S1047951114001711_ref18","doi-asserted-by":"publisher","DOI":"10.1370\/afm.79"},{"key":"S1047951114001711_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2010.03.014"}],"container-title":["Cardiology in the Young"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1047951114001711","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T21:54:53Z","timestamp":1555797293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1047951114001711\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,23]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1047951114001711"],"URL":"https:\/\/doi.org\/10.1017\/s1047951114001711","relation":{},"ISSN":["1047-9511","1467-1107"],"issn-type":[{"value":"1047-9511","type":"print"},{"value":"1467-1107","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,23]]},"assertion":[{"value":"\u00a9 Cambridge University Press 2014\u00a0","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}